This article was originally published in The Rose Sheet
Executive SummaryAdult skin and hair care business grew 14% in the third quarter, including approximately 1% positive currency impact, Johnson & Johnson says during Oct. 18 earnings call. In the U.S., "solid performances from our Neutrogena and RoC brands complemented by very strong results with Aveeno were major drivers of growth," firm notes, adding growth drivers outside the U.S. wereJohnson's adult products, Neutrogena and Clean & Clear anti-acne brand. Baby and kids' care sales grew 7%. Johnson's Bathtime Buddies led 3% revenue growth in the U.S., and Softlotion products and Bathtime Buddies drove 8% growth outside the U.S. Worldwide consumer product sales were $2.23 bil., up 10.2% including a positive currency impact of 1.7%, and U.S. sales in the segment increased 5.1% to $1.08 bil...
You may also be interested in...
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products
Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.
Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.